Bristol-Myers Squibb Company (BMY)
$57.58-2.60%Close
SELLBEAR · day 25
Key stats
Short interest · FINRA settlement 2026-09-30
52-week IV10.9%–47.9%
- Market cap
- $117.6B
- Beta
- 0.23
- Div yield
- 4.23%
- P/E (TTM)
- 13.13
- IV-%ile
- 83
- IV ATM
- 35.4%
- Short % float
- 2.25%
- Days to cover
- 3.0
- SI change
- +9.2%
- 1W
- -2.09%
- 1M
- -8.57%
- vs SPY 1W
- -2.51%
- vs SPY 1M
- -10.63%
Industry peers
FMP comparable companies · ranked by market cap
- LLYBUYEli Lilly and Company$1.1TRECOVERYQ 21$1179.27+0.28%
- JNJSELLJohnson & Johnson$630.0BBEARQ 22$261.44+0.88%
- ABBVBUYAbbVie Inc.$488.5BBULLQ 29$276.47+1.68%
- MRKSELLMerck & Co., Inc.$359.6BBEARQ 11$145.60-0.10%
- NVSBUYNovartis AG$273.2BRECOVERYQ 20$143.75+0.06%
- AZNSELLAstraZeneca PLC$246.9BRECOVERYQ 20$159.20-0.55%
- AMGNBUYAmgen Inc.$223.9BRECOVERYQ 22$414.87+0.65%
- GILDSELLGilead Sciences, Inc.$187.4BBULLQ 25$151.17-0.49%
- PFESELLPfizer Inc.$161.2BBULLQ 13$28.28+0.42%
- GSKSELLGSK plc$93.2BRECOVERYQ 14$46.50+0.90%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 43
- VALUE
- 39
- GROWTH
- 67
- GARP
- 8
- TYPE
- Dividend Compounder
Composite of Value · Growth · GARP
ROIC28.1%
REV YoY-
ROE46.8%
EPS YoY-
ROA10.6%
GROSS70
OP28
NET19
[VALUATION]
P/E TTM13.13
P/E FWD10.28
SECTOR PE20.54
INDUSTRY PE10.18
P/B5.45
P/FCF-
EV/EBITDA9.37
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E193.20
ALTMAN Z-
CURR RATIO1.53
ND/EBITDA-
BETA0.23
Company news
FAQ
- What is LOPJLB’s current signal on BMY?
- LOPJLB’s latest quantitative signal on Bristol-Myers Squibb Company (BMY) is SELL in a BEAR regime. Signals are updated daily.
- What market regime is BMY in?
- Bristol-Myers Squibb Company (BMY) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does Bristol-Myers Squibb Company (BMY) do?
- Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharma…